Skip to main content
Methodology
Visualizing the target estimand in comparative effectiveness studies with multiple treatments
- Gabrielle Simoneau,
- Marian Mitroiu,
- Thomas PA Debray,
- Wei Wei,
- Stan RW Wijn,
- Joana Caldas Magalhães,
- Justin Bohn,
- Changyu Shen,
- Fabio Pellegrini, and
- Carl de Moor
e230089
Published Online:23 January 2024
Short Report
Assessment of second primary malignancies among treated and untreated patients with chronic lymphocytic leukemia using real-world data from the USA
- Sikander Ailawadhi,
- Arliene Ravelo,
- Carmen D Ng,
- Bonny Shah,
- Neil Lamarre,
- Rongrong Wang,
- Katherine Eakle, and
- Juliana ML Biondo
e230119
Published Online:31 January 2024
Research Article
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting
- Alexander Russell-Smith,
- Louise Murphy,
- Amy Nguyen,
- Cori Blauer-Peterson,
- Marilou Terpenning,
- Feng Cao,
- Shiqiang Li,
- Tim Bancroft,
- Noah Webb,
- Stephanie Dorman, and
- Richa Shah
e230142
Published Online:15 December 2023
Justifying the source of external comparators in single-arm oncology health technology submissions: a review of NICE and PBAC assessments
- Katherine Appiah,
- Maria Rizzo,
- Grammati Sarri, and
- Luis Hernandez
e230140
Published Online:4 January 2024
Radiofrequency ablation using the ThermoCool SmartTouch Catheter guided by ablation index versus antiarrhythmic drugs in atrial fibrillation treatment in China: a cost-consequence analysis
- Biqi Zhang,
- Jie Han,
- Dongchen Zhou,
- Jiajia Jiang,
- Jiawei Zhong,
- Yunlong Lu,
- Chenyu Zuo,
- Xingwei Lu,
- Jianwei Xuan,
- Aohan Zu,
- Yuxian He,
- Xingang Sun,
- Lu Chen, and
- Liangrong Zheng
e230035
Published Online:11 January 2024
Estimating utility values for non-alcoholic steatohepatitis health states: a discrete choice experiment
- Daniel Aggio,
- Katy Gallop,
- Villum Wittrup-Jensen,
- Soulmaz Fazeli Farsani, and
- Andrew J Lloyd
e230033
Published Online:16 January 2024
Real-world evidence on the effectiveness and safety of gliclazide MR 60 mg in Bangladeshi patients with Type II diabetes during fasting: a sub-analysis from the global DIA-RAMADAN study
- Mohammed Farid Uddin,
- Murshed Ahamed Khan,
- Shahjada Selim,
- Nusrat Sultana,
- Mohammad Abu Sayem,
- Mohammed Mahboob Iftekhar,
- Maruf Bin Habib,
- Nazma Akter, and
- Shahjamal Khan
e230132
Published Online:31 January 2024
Perspective
Navigating the unknown: how to best ‘reflect’ standard of care in indications without a dedicated treatment pathway in health technology assessment submissions
- Grammati Sarri,
- Maria Rizzo,
- Sheela Upadhyaya,
- Victoria Federico Paly, and
- Luis Hernandez
e230145
Published Online:16 January 2024
Corrigendum
Corrigendum
e240003c1
Published Online:16 January 2024
- Correction(s) for this article
Navigating adalimumab biosimilars: an expert opinion
- Volume 12Issue 11Journal of Comparative Effectiveness Research
- 19 October 2023